Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 16/20 | 0.43 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239337 | 0.83 | APP (0.58) | APPSULT1A1NPC1RAB9A | |
| SCHEMBL21589909 | 0.80 | APP (0.43) | APPSULT1A1KCNH2HRH3 | |
| SCHEMBL21589908 | 0.79 | APP (0.41) | APPSULT1A1NPC1RAB9AKCNH2 | |
| SCHEMBL22130306 | 0.77 | APP (0.69) | APPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL31219275 | 0.77 | APP (0.69) | APPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL24092825 | 0.77 | APP (0.50) | APPSULT1A1MEN1NPC1RAB9A | |
| SCHEMBL19341457 | 0.77 | APP (0.61) | APPSULT1A1NPC1RAB9A | |
| SCHEMBL17801257 | 0.77 | NPC1 (0.60) | NPC1RAB9A | |
| SCHEMBL21589921 | 0.77 | MAOB (0.47) | APPKCNH2HRH3 | |
| SCHEMBL31239316 | 0.77 | MAOB (0.47) | APPKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| WO-2019234243-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | SNCA, PARK7, NLN | APP 42/4885SULT1A1 3167/4885MEN1 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.